Lilly Withdraws India Patent Request For Already-Marketed Forteo (India)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly withdrew a patent request in India for its new-generation biotech drug, Forteo (teriparatide recombinant human) in crystal form for treating osteoporosis. The U.S. company lost an earlier claim for a patent for the $600 million drug in another form when it faced opposition from USV. Lilly already had begun selling the drug in India as the only biotech drug for the disease, with the assumption it would soon have patent protection. USV and at least one other company are expected to launch generics as a result of the patent withdrawal. (Click here for more )